Search
Influenza A virus A/Washington/19/2020 (H1N1) antigen (MDCK cell derived, propiolactone inactivated)
go.drugbank.com/drugs/DB16727ApprovedWithdrawnVaccines provide protection from influenza by exposing the immune system to the virus (or parts of the virus) which stimulates an immunological defence against future exposure to the virus, or "antigen
Nogapendekin alfa
go.drugbank.com/drugs/DB18740ApprovedInvestigationalNogapendekin alfa is a human IL-15N72D variant. It is one of the active ingredients in Anktiva, a combination product also containing inbakicept, where a single inbakicept is complexed with two nogapendekin alfa components. This combinat...
Synonyms: Human interleukin 15 (72-aspartic acid) (human il-15 n72>d isoform), Il-15n72d:il-15rec-su/fc soluble complex iInfluenza B virus B/Brisbane/60/2008 antigen (UV, formaldehyde inactivated)
go.drugbank.com/drugs/DB10598ApprovedWithdrawnVaccines provide protection from influenza by exposing the immune system to the virus (or parts of the virus) which stimulates an immunological defence against future exposure to the virus, or "antigen
Influenza B virus B/Phuket/3073/2013 antigen (UV, formaldehyde inactivated)
go.drugbank.com/drugs/DB10599ApprovedWithdrawnVaccines provide protection from influenza by exposing the immune system to the virus (or parts of the virus) which stimulates an immunological defence against future exposure to the virus, or "antigen
Influenza A virus A/South Australia/55/2014 IVR-175 (H3N2) antigen (propiolactone inactivated)
go.drugbank.com/drugs/DB10601ApprovedWithdrawnVaccines provide protection from influenza by exposing the immune system to the virus (or parts of the virus) which stimulates an immunological defence against future exposure to the virus, or "antigen
Influenza B virus B/Phuket/3073/2013 antigen (propiolactone inactivated)
go.drugbank.com/drugs/DB10602ApprovedWithdrawnVaccines provide protection from influenza by exposing the immune system to the virus (or parts of the virus) which stimulates an immunological defence against future exposure to the virus, or "antigen
Influenza A virus A/California/7/2009 (H1N1) recombinant hemagglutinin antigen
go.drugbank.com/drugs/DB10773ApprovedInvestigationalWithdrawnVaccines provide protection from influenza by exposing the immune system to the virus (or parts of the virus) which stimulates an immunological defence against future exposure to the virus, or "antigen
Influenza B virus B/Phuket/3073/2013 recombinant hemagglutinin antigen
go.drugbank.com/drugs/DB10779ApprovedInvestigationalVaccines provide protection from influenza by exposing the immune system to the virus (or parts of the virus) which stimulates an immunological defence against future exposure to the virus, or "antigen
Influenza A virus A/California/7/2009 X-179A (H1N1) antigen (formaldehyde inactivated)
go.drugbank.com/drugs/DB10791ApprovedInvestigationalWithdrawnVaccines provide protection from influenza by exposing the immune system to the virus (or parts of the virus) which stimulates an immunological defence against future exposure to the virus, or "antigen
Influenza B virus B/Brisbane/60/2008 antigen (formaldehyde inactivated)
go.drugbank.com/drugs/DB10794ApprovedInvestigationalWithdrawnVaccines provide protection from influenza by exposing the immune system to the virus (or parts of the virus) which stimulates an immunological defence against future exposure to the virus, or "antigen